This study will assess the safety, tolerability and efficacy of SAF312 in patients with
overactive bladder disease due to spinal cord lesions. The overactive bladder of patients who
qualify for this study is insufficiently managed by antimuscarinic therapy, or patients
poorly tolerate the treatment with antimuscarinic drugs. The efficacy of SAF312 will be
primarily determined via urodynamic measurements.